Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine

被引:46
作者
Kosoglou, T
Salfi, M
Lim, JM
Batra, VK
Cayen, MN
Affrime, MB
机构
[1] Schering Plough Corp, Res Inst, Dept Clin Pharmacol, Kenilworth, NJ 07033 USA
[2] Schering Plough Corp, Res Inst, Dept Biostat, Kenilworth, NJ 07033 USA
[3] Schering Plough Corp, Res Inst, Dept Drug Metab & Pharmacokinet, Kenilworth, NJ 07033 USA
关键词
cimetidine; electrocardiographic; ketoconazole; loratadine; repolarization;
D O I
10.1046/j.1365-2125.2000.00290.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To evaluate whether ketoconazole or cimetidine alter the pharmacokinetics of loratadine, or its major metabolite, desloratadine (DCL), or alter the effects of loratadine or DCL on electrocardiographic repolarization in healthy adult volunteers. Methods Two randomized, evaluator-blind, multiple-dose. three-way crossover drug interaction studies were performed. In each study, subjects received three 10 day treatments in random sequence, separated by a 14 day washout period. The treatments were loratadine alone, cimetidine or ketoconazole alone, or loratadine plus cimetidine or ketoconazole. The primary study endpoint was the difference in mean QTc intervals from baseline to day 10. In addition, plasma concentrations of loratadine, DCL, and ketoconazole or cimetidine were obtained on day 10. Results Concomitant administration of loratadine and ketoconazole significantly increased the loratadine plasma concentrations (307%; 90% CI 205-428%) and DCL concentrations (73%; 62-85%) compared with administration of loratadine alone. Concomitant administration of loratadine and cimetidine significantly increased the loratadine plasma concentrations (103% increase; 70-142%) but not DCL concentrations (6% increase; 1-11%) compared with administration of loratadine alone. Cimetidine or ketoconazole plasma concentrations were unaffected by coadministration with loratadine. Despite increased concentrations of loratadine and DCL, there were no statistically significant differences for the primary electro cardiographic repolarization parameter (QTc) among any of the treatment groups. No other clinically relevant changes in the safety profile of loratadine were observed as assessed by electrocardiographic parameters (mean (90% CI) QTc changes: loratadine vs loratadine + ketoconazole = 3.6 ms (-2.2, 9.4); loratadine vs loratadine + cimetidine = 3.2 ms (-1.6, 7.9)), clinical laboratory tests, vital signs, and adverse events. Conclusions Loratadine 10 mg daily was devoid of any effects on electrocardiographic parameters when coadministered for 10 days with therapeutic doses of ketoconazole or cimetidine in healthy volunteers. It is concluded that, although there was a significant pharmacokinetic drug interaction between ketoconazole or cimetidine and loratadine, this effect was not accompanied by a change in the QTc interval in healthy adult volunteers.
引用
收藏
页码:581 / 589
页数:9
相关论文
共 23 条
[1]  
AFFRIME MB, 1993, ALLERGY S16, V48, P29
[2]   REGULATION OF POTASSIUM CHANNELS BY NONSEDATING ANTIHISTAMINES [J].
BERUL, CI ;
MORAD, M .
CIRCULATION, 1995, 91 (08) :2220-2225
[3]   LORATADINE ADMINISTERED CONCOMITANTLY WITH ERYTHROMYCIN - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC EVALUATIONS [J].
BRANNAN, MD ;
REIDENBERG, P ;
RADWANSKI, E ;
SHNEYER, L ;
LIN, CC ;
CAYEN, MN ;
AFFRIME, MB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (03) :269-278
[4]   Dangers of non-sedating antihistamines [J].
Clark, S .
LANCET, 1997, 349 (9061) :1268-1268
[5]   Description and evaluation of the vallecula sign: A new radiologic sign in the diagnosis of adult epiglottitis [J].
Ducic, Y ;
Hebert, PC ;
MacLachlan, L ;
Neufeld, K ;
Lamothe, A .
ANNALS OF EMERGENCY MEDICINE, 1997, 30 (01) :1-6
[6]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[7]   ANTIHISTAMINE ACTIVITY, CENTRAL-NERVOUS-SYSTEM AND CARDIOVASCULAR PROFILES OF HISTAMINE H-1 ANTAGONISTS - COMPARATIVE-STUDIES WITH LORATADINE, TERFENADINE AND SEDATING ANTIHISTAMINES IN GUINEA-PIGS [J].
HEY, JA ;
DELPRADO, M ;
CUSS, FM ;
EGAN, RW ;
SHERWOOD, J ;
LIN, CC ;
KREUTNER, W .
CLINICAL AND EXPERIMENTAL ALLERGY, 1995, 25 (10) :974-984
[8]   PHARMACOKINETICS AND DOSE PROPORTIONALITY OF LORATADINE [J].
HILBERT, J ;
RADWANSKI, E ;
WEGLEIN, R ;
LUC, V ;
PERENTESIS, G ;
SYMCHOWICZ, S ;
ZAMPAGLIONE, N .
JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (09) :694-698
[9]   CHANGES IN THE PHARMACOKINETICS AND ELECTROCARDIOGRAPHIC PHARMACODYNAMICS OF TERFENADINE WITH CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN [J].
HONIG, PK ;
WOOSLEY, RL ;
ZAMANI, K ;
CONNER, DP ;
CANTILENA, LR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (03) :231-238
[10]   TERFENADINE-KETOCONAZOLE INTERACTION - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES [J].
HONIG, PK ;
WORTHAM, DC ;
ZAMANI, K ;
CONNER, DP ;
MULLIN, JC ;
CANTILENA, LR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (12) :1513-1518